|
|
Upfront Briefing
Regeneron had itself a day: FDA approved its genetic hearing-loss gene therapy Otarmeni — and the company says it’ll provide the drug for free in the U.S.
Then it announced a separate agreement with the U.S. government tied to lowering drug costs, while AbbVie disclosed an FDA CRL for TrenibotE tied to manufacturing. Nothing like policy + CMC risk to keep models honest.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,108.4 |
(0.4%) |
+2.8% |
| Nasdaq 100 |
26,782.6 |
(0.6%) |
+4.6% |
| Russell 2000 |
2,775.1 |
(0.4%) |
+4.0% |
| Healthcare (XLV) |
146.2 |
(0.1%) |
(6.8%) |
| Biotech (XBI) |
134.5 |
(2.1%) |
+5.0% |
| Nasdaq Biotech (NBI) |
5,965.0 |
(1.4%) |
+0.5% |
| Clinical Trials (BBC) |
46.3 |
(2.2%) |
+8.2% |
|
- Biotech caught the worst of Thursday's risk-off: XBI fell 2.1% and Clinical Trials (BBC) fell 2.2%, well worse than the S&P 500's modest 0.4% pullback. The macro set-up was a software-led tech unwind — ServiceNow slumped ~17.8% and IBM fell ~8.2% on mixed earnings — layered on top of oil pushing back above $96 WTI / $105 Brent as U.S.–Iran talks stalled and Strait of Hormuz mine-laying concerns resurfaced.
- Large-cap healthcare was the relative safe harbor: XLV down just 0.1% vs XBI -2.1%, suggesting the move was a smallcap/high-beta de-risking rather than a defensive-healthcare rotation. Notably, MFN-deal-of-the-day Regeneron actually rose on the session — TD Cowen raised its price target to $960 from $880 — which argues Wall Street read the Regeneron agreement as manageable rather than a fresh sector-wide pricing overhang.
- Market data: U.S. close Thu 23-Apr-2026.
The Big 3
|
1
|
FDA approves Regeneron gene therapy Otarmeni for hearing loss
|
- FDA approved Regeneron's Otarmeni (lunsotogene parvec-cwha), a gene therapy for an ultra-rare form of genetic hearing loss (otoferlin-related), and Regeneron said it will provide the therapy for free in the U.S. — excluding administration costs, which patients work out with providers/payers.
- Why it matters: The economics of "free" are better than they look. The treatable population is ultra-rare (low thousands), the asset came from Regeneron's $213M Decibel acquisition in 2023, and the approval carries a rare pediatric priority review voucher worth an estimated $200M+ based on recent Jazz ($200M) and Fortress ($205M) voucher sales. Otarmeni is also the first gene therapy approved under FDA's new National Priority Voucher pilot — 61 days from BLA to accelerated approval — which validates Regeneron's regulatory execution and positions its earlier-stage hearing-loss gene therapies (from the Decibel deal) for faster paths. The accelerated approval does require post-marketing data on durability and speech development, which will set the template for the next wave of inherited-hearing-loss launches.
- Source: Endpoints
- More: BioPharma Dive; BioSpace; PR
|
|
2
|
Regeneron reaches U.S. government drug-cost agreement
|
- Regeneron signed an MFN (Most-Favored-Nation) agreement with the U.S. government — becoming the 17th and final large pharma of the 17 companies targeted by the July 2025 White House letters. Key terms: Praluent cut from $537 to $225 for patients buying through TrumpRx.gov; Medicaid prices aligned to MFN levels; all new Regeneron drugs will launch at MFN prices in the U.S.; and Regeneron committed to $27B in U.S. manufacturing and R&D investment.
- Why it matters: This is the closing chapter, not the opening one — with Regeneron signed, MFN deals now cover roughly 86% of branded pharmaceutical sales in the U.S. The investor debate shifts accordingly: no longer "which company signs next" but (i) how aggressively MFN expands beyond Medicaid into Medicare or commercial channels, (ii) how launch economics change now that all new drugs from these 17 companies are gated to MFN at launch, and (iii) whether the $27B-style U.S. investment commitments become a standard ask for any remaining tariff/access relief. Notably, the market read the deal as benign: REGN rose on the session and TD Cowen raised its price target to $960 from $880, implying Wall Street views the Praluent concession and Otarmeni giveaway as manageable relative to Eylea/Dupixent economics.
- Source: STAT
- More: Fierce Pharma; Axios; PR
|
| 3 | AbbVie gets FDA CRL for TrenibotE BLA tied to manufacturing |
- AbbVie disclosed that FDA issued a complete response letter for TrenibotE (trenibotulinumtoxinE), its rapid-onset, short-duration serotype E botulinum neurotoxin BLA for glabellar lines. The CRL is tied to manufacturing processes only; no additional clinical studies were requested. The BLA was supported by two pivotal Phase 3 trials and long-term safety data.
- Why it matters: The CRL preserves the clinical package but pushes TrenibotE's commercial launch into CMC-remediation territory, which historically takes 6–12 months. The strategic logic of TrenibotE is to complement — not cannibalize — Botox by offering a differentiated short-duration profile (days-to-weeks rather than months) aimed at first-time toxin users and event-driven aesthetic demand; any launch delay prolongs competitor Revance's runway with Daxxify and keeps AbbVie's aesthetics refresh gap open. For investors in the ~$63B Allergan acquisition thesis, the read-through is a timing and remediation question, not a demand question — but CMC CRLs in AbbVie's toxin franchise are worth tracking closely given the scale of Botox's contribution to aesthetics revenue.
- Source: PR
|
Everything Else that broke
- Grace Therapeutics gets FDA CRL for GTx-104 NDA. — PR
- Novartis Coartem Baby receives WHO prequalification. — PR
- CLINUVEL gets final EMA scientific advice for Phase III vitiligo study. — PR
- Tempero Bio to close after earlier 'serious' safety event. — Endpoints
- Novartis' Lutathera could soon face generic competition. — Endpoints
- AbbVie to build $1.4B manufacturing campus in North Carolina. — BioPharma Dive
- Tivic Health Systems rebrands as Valion Bio; ticker to change. — PR
- Moderna wins EU approval for flu/COVID-19 combo shot, a notable regulatory milestone even as the U.S. combo-vaccine pathway remains delayed. — BioSpace
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Amneal’s $1.1B Kashiv buyout remained in the deal-tape conversation, giving the company a larger biosimilars platform and pipeline; included here as follow-through after first appearing in Thursday’s edition. — Reuters
-
Cumberland Pharmaceuticals agreed to sell its U.S. branded pharmaceutical portfolio (Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, Vaprisol, Talicia) to Apotex for $100M in cash, with Cumberland retaining its ifetroban clinical pipeline and majority stake in Cumberland Emerging Technologies. Cumberland shares surged intraday, closing up ~23%. Subject to shareholder approval (~41% already locked via voting agreements); long-stop date Aug 20, 2026. — PR
-
Eli Lilly walked away from the rest of its up-to-$960M RIPK1 partnership with Rigel Pharmaceuticals (originally signed Feb 2021, $125M upfront), returning full rights to lead asset ocadusertib and other RIPK1 inhibitors; termination effective June 15, 2026. Follows Lilly's November 2025 exit from the CNS portion and adds to a broader pharma pullback from the RIPK1 modality. — Endpoints
- Rumour watch: Sun Pharma has reportedly submitted a binding $13B bid for Organon, according to Economic Times — more pharma than core biotech, but notable broader deal-tape colour. — Economic Times
VC / Private Financings
- Ray Therapeutics closed an upsized, oversubscribed $125M Series B for optogenetic vision-restoration gene therapies (lead RTx-015 in retinitis pigmentosa, RTx-021 in Stargardt/GA). Led by Janus Henderson Investors, with new investors Adage Capital Management, Franklin Templeton, Invus and Marshall Wace; existing backers 4BIO Capital, Deerfield Management, MRL Ventures (Merck), Norwest, Novo Holdings and Platanus followed on. — PR
- Tortugas Neuroscience launched with $106M across seed and Series A financing to advance clinical-stage neurology assets licensed from Eisai and Hansoh; Cure Ventures led the seed, with Cure, The Column Group and AN Venture Partners co-leading the Series A. — BioPharma Dive
- Flagship Pioneering launched Serif Biomedicines out of its foundry with $50M to develop modified-DNA medicines — a next-generation programmable nucleic-acid therapeutic class positioned as a successor/complement to mRNA platforms. — BioPharma Dive
IPOs / Follow-Ons
- Nektar closes $373.8M public offering. — PR
- Bioretec announced preliminary results of its rights issue, with final results expected around 24 April. — PR
Academic Corner
- Intestinal metaplasia is the only precursor to esophageal adenocarcinoma. — Nature Medicine
|
|
That’s it for today — may your access strategy be optional, not mandatory. See you next edition. BioBucks Team
|
|
|
